Treatment paradigms for cataplexy in narcolepsy: past, present, and future

References

• McCartyDEA case of narcolepsy with strictly unilateral cataplexyJ Clin Sleep Med201061757620191942
   PubMed Web of Science ®Google Scholar
• OvereemSvan NuesSJvan der ZandeWLDonjacourCEvan MierloPLammersGJThe clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiencySleep Med2011121121821145280
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological Disorders and StrokeNarcolepsy Fact SheetNIH publication 13-1637 last updated January 5, 2015 Available from: http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm#241213201Accessed August 9, 2015
   Google Scholar
• PoryazovaRKhatamiRWerthEBassettiCLWeak with sex: sexual intercourse as a trigger for cataplexyJ Sex Med2009682271227719493288
   PubMed Web of Science ®Google Scholar
• SturzeneggerCBassettiCLThe clinical spectrum of narcolepsy with cataplexy: a reappraisalJ Sleep Res200413439540615560774
   PubMed Web of Science ®Google Scholar
• OkunMLLinLPelinZHongSMignotEClinical aspects of narcolepsy-cataplexy across ethnic groupsSleep2002251273511833858
   PubMed Web of Science ®Google Scholar
• Martinez-RodriguezJIranzoASantamariaJStatus cataplecticus induced by abrupt withdrawal of clomipramineNeurologia2002172113116 Spanish11864561
   PubMed Web of Science ®Google Scholar
• WangJGreenbergHStatus cataplecticus precipitated by abrupt withdrawal of venlafaxineJ Clin Sleep Med20139771571623853567
   PubMed Web of Science ®Google Scholar
• DauvilliersYSiegelJMLopezRTorontaliZAPeeverJHCataplexy – clinical aspects, pathophysiology and management strategyNat Rev Neurol201410738639524890646
   PubMed Web of Science ®Google Scholar
• NishinoSClinical and neurobiological aspects of narcolepsySleep Med20078437339917470414
   PubMed Web of Science ®Google Scholar
• LongstrethWTJrKoepsellTDTonTGHendricksonAFvan BelleGThe epidemiology of narcolepsySleep2007301132617310860
   PubMed Web of Science ®Google Scholar
• DauvilliersYMontplaisirJMolinariNAge at onset of narcolepsy in two large populations of patients in France and QuebecNeurology200157112029203311739821
   PubMed Web of Science ®Google Scholar
• American Academy of Sleep MedicineThe International Classification of Sleep Disorders – Third Edition (ICSD-3)Darien, ILAmerican Academy of Sleep Medicine2014
   Google Scholar
• AdamantidisARZhangFAravanisAMDeisserothKde LeceaLNeural substrates of awakening probed with optogenetic control of hypocretin neuronsNature2007450716842042417943086
   PubMed Web of Science ®Google Scholar
• EspanaRAScammellTESleep neurobiology from a clinical perspectiveSleep201134784585821731134
   PubMed Web of Science ®Google Scholar
• SerraLMontagnaPMignotELugaresiEPlazziGCataplexy features in childhood narcolepsyMov Disord200823685886518307264
   PubMed Web of Science ®Google Scholar
• AndlauerOMooreHtHongSCPredictors of hypocretin (orexin) deficiency in narcolepsy without cataplexySleep20123591247125522942503
   PubMed Web of Science ®Google Scholar
• NevsimalovaSPiskoJBuskovaJNarcolepsy: clinical differences and association with other sleep disorders in different age groupsJ Neurol2013260376777523070467
   PubMed Web of Science ®Google Scholar
• PlazziGPizzaFPalaiaVComplex movement disorders at disease onset in childhood narcolepsy with cataplexyBrain2011134Pt 1234803492
   Web of Science ®Google Scholar
• PizzaFFranceschiniCPeltolaHClinical and polysomnographic course of childhood narcolepsy with cataplexyBrain2013136Pt 123787379524142146
   PubMed Web of Science ®Google Scholar
• VanierMTNiemann-Pick diseasesHandb Clin Neurol20131131717172123622394
   PubMedGoogle Scholar
• TobiasESTolmieJLStephensonJBCataplexy in the Prader-Willi syndromeArch Dis Child200287217012138077
   PubMed Web of Science ®Google Scholar
• NelsonGBHahnJSStimulus-induced drop episodes in Coffin-Lowry syndromePediatrics20031113e197e20212612271
   PubMed Web of Science ®Google Scholar
• FryssiraHKountoupiSDelaunoyJPThomaidisLA female with Coffin-Lowry syndrome and “cataplexy”Genet Couns200213440540912558110
   PubMed Web of Science ®Google Scholar
• TyagiAHarringtonHCataplexy in association with Moebius syndromeJ Neurol2003250111011112528006
   PubMed Web of Science ®Google Scholar
• VosslerDGWylerARWilkusRJGardner-WalkerGVlcekBWCataplexy and monoamine oxidase deficiency in Norrie diseaseNeurology1996465125812618628463
   PubMed Web of Science ®Google Scholar
• PortalaKWestermarkKEkseliusLBromanJESleep in patients with treated Wilson’s disease. A questionnaire studyNord J Psychiatry200256429129712470321
   PubMed Web of Science ®Google Scholar
• NevsimalovaSBuskovaJBruhaRSleep disorders in Wilson’s diseaseEur J Neurol201118118419020550561
   PubMed Web of Science ®Google Scholar
• KanbayashiTAbeMFujimotoSHypocretin deficiency in Niemann-Pick type C with cataplexyNeuropediatrics2003341525312690569
   PubMed Web of Science ®Google Scholar
• OyamaKTakahashiTShojiYNiemann-Pick disease type C: cataplexy and hypocretin in cerebrospinal fluidTohoku J Exp Med2006209326326716778374
   PubMed Web of Science ®Google Scholar
• VankovaJStepanovaIJechRSleep disturbances and hypocretin deficiency in Niemann-Pick disease type CSleep200326442743012841368
   PubMed Web of Science ®Google Scholar
• PeyronCTigheDKvan den PolANNeurons containing hypocretin (orexin) project to multiple neuronal systemsJ Neurosci199818239996100159822755
   PubMed Web of Science ®Google Scholar
• CasonAMSmithRJTahsili-FahadanPMoormanDESartorGCAston-JonesGRole of orexin/hypocretin in reward-seeking and addiction: implications for obesityPhysiol Behav2010100541942820338186
   PubMed Web of Science ®Google Scholar
• BurgessCRScammellTENarcolepsy: neural mechanisms of sleepiness and cataplexyJ Neurosci20123236123051231122956821
   PubMed Web of Science ®Google Scholar
• MiedaMTsujinoNSakuraiTDifferential roles of orexin receptors in the regulation of sleep/wakefulnessFront Endocrinol (Lausanne)201345723730297
   PubMedGoogle Scholar
• InutsukaAInuiATabuchiSTsunematsuTLazarusMYamanakaAConcurrent and robust regulation of feeding behaviors and metabolism by orexin neuronsNeuropharmacology20148545146024951857
   PubMed Web of Science ®Google Scholar
• PeyronCFaracoJRogersWA mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brainsNat Med20006999199710973318
   PubMed Web of Science ®Google Scholar
• PeeverJHLaiYYSiegelJMExcitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonismJ Neurophysiol20038952591260012611960
   PubMed Web of Science ®Google Scholar
• DauvilliersYJaussentILecendreuxMCerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: a case-control studyBrain Behav Immun201426026624394344
   PubMed Web of Science ®Google Scholar
• LeeMGHassaniOKJonesBEDischarge of identified orexin/hypocretin neurons across the sleep-waking cycleJ Neurosci200525286716672016014733
   PubMed Web of Science ®Google Scholar
• TakahashiKLinJSSakaiKNeuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouseNeuroscience2008153386087018424001
   PubMed Web of Science ®Google Scholar
• LinLFaracoJLiRThe sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 geneCell199998336537610458611
   PubMed Web of Science ®Google Scholar
• ChemelliRMWillieJTSintonCMNarcolepsy in orexin knockout mice: molecular genetics of sleep regulationCell199998443745110481909
   PubMed Web of Science ®Google Scholar
• NishinoSRipleyBOvereemSLammersGJMignotEHypocretin (orexin) deficiency in human narcolepsyLancet200035591973940 Letter10615891
   PubMed Web of Science ®Google Scholar
• TabuchiSTsunematsuTBlackSWConditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system functionJ Neurosci201434196495650924806676
   PubMed Web of Science ®Google Scholar
• PizzaFVandiSLiguoriRPrimary progressive narcolepsy type 1: the other side of the coinNeurology201483232189219025355832
   PubMed Web of Science ®Google Scholar
• NishinoSOkuroMKotoriiNHypocretin/orexin and narcolepsy: new basic and clinical insightsActa Physiol (Oxf)2010198320922219555382
   PubMed Web of Science ®Google Scholar
• PartinenMKornumBRPlazziGJennumPJulkunenIVaaralaODoes autoreactivity have a role in narcolepsy?Lancet Neurol2014131110721073 Letter25316012
   PubMed Web of Science ®Google Scholar
• MignotEHaydukRBlackJGrumetFCGuilleminaultCHLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patientsSleep19972011101210209456467
   PubMed Web of Science ®Google Scholar
• HallmayerJFaracoJLinLNarcolepsy is strongly associated with the T-cell receptor alpha locusNat Genet200941670871119412176
   PubMed Web of Science ®Google Scholar
• FaracoJLinLKornumBRImmunoChip study implicates antigen presentation to T cells in narcolepsyPLoS Genet201392e100327023459209
   PubMed Web of Science ®Google Scholar
• AhmedSSVolkmuthWDucaJAntibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2Sci Transl Med20157294294ra105
   PubMed Web of Science ®Google Scholar
• GulyaniSWuMFNienhuisRJohnJSiegelJMCataplexy-related neurons in the amygdala of the narcoleptic dogNeuroscience2002112235536512044453
   PubMed Web of Science ®Google Scholar
• HongSBTaeWSJooEYCerebral perfusion changes during cataplexy in narcolepsy patientsNeurology200666111747174916769955
   PubMed Web of Science ®Google Scholar
• OvereemSLammersGJvan DijkJGCataplexy: ‘tonic immobility’ rather than ‘REM-sleep atonia’?Sleep Med20023647147714592141
   PubMedGoogle Scholar
• OvereemSReijntjesRHuyserWLammersGJvan DijkJGCorticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atoniaJ Sleep Res200413325726415339261
   PubMed Web of Science ®Google Scholar
• SchwartzSPonzAPoryazovaRAbnormal activity in hypothalamus and amygdala during humour processing in human narcolepsy with cataplexyBrain2008131Pt 251452218094020
   PubMed Web of Science ®Google Scholar
• BurgessCROishiYMochizukiTPeeverJHScammellTEAmygdala lesions reduce cataplexy in orexin knock-out miceJ Neurosci201333239734974223739970
   PubMed Web of Science ®Google Scholar
• DauvillersYBilliardMMontplaisirJClinical aspects and pathophysiology of narcolepsyClin Neurophysiol20031142000201714580598
   PubMed Web of Science ®Google Scholar
• PeeverJControl of motoneuron function and muscle tone during REM sleep, REM sleep behavior disorder and cataplexy/narcolepsyArch Ital Biol2011149445446622205591
   PubMed Web of Science ®Google Scholar
• SiegelJMNienhuisRFahringerHMNeuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medullaScience19912525010131513181925546
   PubMed Web of Science ®Google Scholar
• LuppiPHClementOSapinEThe neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorderSleep Med Rev201115315316321115377
   PubMed Web of Science ®Google Scholar
• NishinoSTaftiMReidMSMuscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsyJ Neurosci1995157 Pt 1480648147623112
   PubMed Web of Science ®Google Scholar
• ThorpyMJKriegerACDelayed diagnosis of narcolepsy: characterization and impactSleep Med20141550250724780133
   PubMed Web of Science ®Google Scholar
• Anic-LabatSGuilleminaultCKraemerHCMeehanJArrigoniJMignotEValidation of a cataplexy questionnaire in 983 sleep-disorders patientsSleep199922177879989368
   PubMed Web of Science ®Google Scholar
• MooreWRSilberMHDeckerPACataplexy Emotional Trigger Questionnaire (CETQ) – a brief patient screen to identify cataplexy in patients with narcolepsyJ Clin Sleep Med200731374017557451
   PubMed Web of Science ®Google Scholar
• PrinzmetalMBloombergWThe use of benzedrine for the treatment of narcolepsyJAMA19351052020512054
   Google Scholar
• ParkesJDFentonGWLevo(–) amphetamine and dextro(+) amphetamine in the treatment of narcolepsyJ Neurol Neurosurg Psychiatry1973366107610814359162
   PubMed Web of Science ®Google Scholar
• DalyDDYossREThe treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary reportProc Staff Meet Mayo Clin1956312362062513379528
   PubMed Web of Science ®Google Scholar
• AkimotoHHondaYTakahashiYPharmacotherapy in narcolepsyDis Nerv Syst19602170470613681922
   PubMedGoogle Scholar
• HishikawaYIdaHNakaiKKanekoZTreatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran)J Neurol Sci1966354534614380880
   PubMed Web of Science ®Google Scholar
• ShapiroWRTreatment of cataplexy with clomipramineTrans Am Neurol Assoc197499991024463568
   PubMedGoogle Scholar
• GuilleminaultCRaynalDTakahashiSCarskadonMDementWEvaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochlorideActa Neurol Scand19765417187936975
   PubMed Web of Science ®Google Scholar
• ParkesJDSchachterMClomipramine and clonazepam in cataplexyLancet1979281511085108691833
   PubMed Web of Science ®Google Scholar
• SchachterMParkesJDFluvoxamine and clomipramine in the treatment of cataplexyJ Neurol Neurosurg Psychiatry19804321711746766990
   PubMed Web of Science ®Google Scholar
• LangdonNShindlerJParkesJDBandakSFluoxetine in the treatment of cataplexySleep1986923713733509809
   PubMed Web of Science ®Google Scholar
• ChenSYCliftSJDahlitzMJDunnGParkesJDTreatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramineJ Sleep Res19954211311810607149
   PubMed Web of Science ®Google Scholar
• WinokurAGaryKARodnerSRae-RedCFernandoATSzubaMPDepression, sleep physiology, and antidepressant drugsDepress Anxiety2001141192811568979
   PubMed Web of Science ®Google Scholar
• MorgenthalerTIKapurVKBrownTPractice parameters for the treatment of narcolepsy and other hypersomnias of central originSleep200730121705171118246980
   PubMed Web of Science ®Google Scholar
• BilliardMBassettiCDauvilliersYEFNS guidelines on management of narcolepsyEur J Neurol 2006/10200613101035104816987156
   PubMed Web of Science ®Google Scholar
• Xyrem^® [sodium oxybate] oral solution US prescribing informationPalo Alto, CAJazz Pharmaceuticals, Inc42014
   Google Scholar
• MignotENishinoSEmerging therapies in narcolepsy-cataplexySleep200528675476316477963
   PubMed Web of Science ®Google Scholar
• BroughtonRMamelakMEffects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexyCan J Neurol Sci19807123317388696
   PubMed Web of Science ®Google Scholar
• MamelakMScharfMBWoodsMTreatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findingsSleep198691 Pt 22852893704454
   PubMed Web of Science ®Google Scholar
• PardiDBlackJγ-Hydroxybutyrate/sodium oxybate. Neurobiology, and impact on sleep and wakefulnessCNS Drugs20062012993101817140279
   PubMed Web of Science ®Google Scholar
• HuangYSGuilleminaultCNarcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybatePediatr Neurol200941191619520267
   PubMed Web of Science ®Google Scholar
• MignotEJA practical guide to the therapy of narcolepsy and hypersomnia syndromesNeurotherapeutics20129473975223065655
   PubMed Web of Science ®Google Scholar
• GowdaCRLundtLPMechanism of action of narcolepsy medicationsCNS Spectr201419Suppl 1253425403789
   PubMed Web of Science ®Google Scholar
• MignotERenaudANishinoSArrigoniJGuilleminaultCDementWCCanine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancersPsychopharmacology (Berl)1993113176827862832
   PubMed Web of Science ®Google Scholar
• NishinoSArrigoniJSheltonJDementWCMignotEDesmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compoundsSleep19931687067128165384
   PubMed Web of Science ®Google Scholar
• NishinoSFruhstorferBArrigoniJGuilleminaultCDementWCMignotEFurther characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsyJ Pharmacol Exp Ther19932643107910848095546
   PubMed Web of Science ®Google Scholar
• LammersGJArendsJDeclerckACFerrariMDSchouwinkGTroostJGammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled studySleep19931632162208506453
   PubMed Web of Science ®Google Scholar
• The US Xyrem Multi-Center Study GroupA randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsySleep200225424911833860
   PubMed Web of Science ®Google Scholar
• Xyrem International Study GroupFurther evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patientsSleep Med20056541542116099718
   PubMed Web of Science ®Google Scholar
• US Xyrem Multicenter Study GroupA 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsySleep2003261313512627729
   PubMed Web of Science ®Google Scholar
• US Xyrem Multicenter Study GroupSodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsySleep Med20045211912315033130
   PubMed Web of Science ®Google Scholar
• AlshaikhMKTriccoACTashkandiMMamdaniMStrausSEBahammamASSodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysisJ Clin Sleep Med20128445145822893778
   PubMed Web of Science ®Google Scholar
• Boscolo-BertoRVielGMontagneseSRaduazzoDIFerraraSDDauvilliersYNarcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trialsSleep Med Rev201216543144322055895
   PubMed Web of Science ®Google Scholar
• MansukhaniMPKotagalSSodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective studySleep Med20121360661022445591
   PubMed Web of Science ®Google Scholar
• CorkeryJMLoiBClaridgeHGamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical useNeurosci Biobehav Rev201553527825843781
   PubMed Web of Science ®Google Scholar
• VignatelliLD’AlessandroRCandeliseLAntidepressant drugs for narcolepsyCochrane Database Syst Rev20081CD00372418254030
   PubMed Web of Science ®Google Scholar
• FreyJDarbonneCFluoxetine suppresses human cataplexy: a pilot studyNeurology19944447077098164831
   PubMed Web of Science ®Google Scholar
• IzziFPlacidiFMarcianiMGEffective treatment of narcolepsy-cataplexy with duloxetine: a report of three casesSleep Med2009101153154 Letter18226953
   PubMed Web of Science ®Google Scholar
• MollerLROstergaardJRTreatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinationsJ Child Adolesc Psychopharmacol200919219720119364297
   PubMed Web of Science ®Google Scholar
• RatkiewiczMSplaingardMTreatment of cataplexy in a three-year-old using venlafaxineJ Clin Sleep Med201391213411342 Case report24340297
   PubMed Web of Science ®Google Scholar
• SonkaKKemlinkDPretlMCataplexy treated with escitalopram – clinical experienceNeuro Endocrinol Lett2006271–217417616648807
   PubMed Web of Science ®Google Scholar
• KaracanIErectile dysfunction in narcoleptic patientsSleep198691 Pt 22272313704447
   PubMed Web of Science ®Google Scholar
• JuYELarson-PriorLDuntleySChanging demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressantsSleep Med201112327828321317035
   PubMed Web of Science ®Google Scholar
• PoryazovaRSiccoliMWerthEBassettiCLUnusually prolonged rebound cataplexy after withdrawal of fluoxetineNeurology200565696796816186554
   PubMed Web of Science ®Google Scholar
• RistanovicRKLiangHHornfeldtCSLaiCExacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexySleep Med200910441642118753005
   PubMed Web of Science ®Google Scholar
• JohnJWuMFBoehmerLNSiegelJMCataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behaviorNeuron200442461963415157423
   PubMed Web of Science ®Google Scholar
• ValkoPOGavrilovYVYamamotoMIncrease of histaminergic tuberomammillary neurons in narcolepsyAnn Neurol201374679480424006291
   PubMed Web of Science ®Google Scholar
• LinJSDauvilliersYArnulfIAn inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patientsNeurobiol Dis2008301748318295497
   PubMed Web of Science ®Google Scholar
• DauvilliersYBassettiCLammersGJPitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trialLancet Neurol201312111068107524107292
   PubMed Web of Science ®Google Scholar
• InocenteCArnulfIBastujiHPitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepinessClin Neuropharmacol2012352556022356925
   PubMed Web of Science ®Google Scholar
• BaierPCHallschmidMSeeck-HirschnerMEffects of intra-nasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexySleep Med2011121094194622036605
   PubMed Web of Science ®Google Scholar
• WeinholdSLSeeck-HirschnerMNowakAHallschmidMGoderRBaierPCThe effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexyBehav Brain Res201426281324406723
   PubMed Web of Science ®Google Scholar
• JohnJWuMFSiegelJMSystemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogsSleep Res Online200031232811382896
   PubMedGoogle Scholar
• BlackSWMorairtySRChenTMGABAB agonism promotes sleep and reduces cataplexy in murine narcolepsyJ Neurosci201434196485649424806675
   PubMed Web of Science ®Google Scholar
• FronczekRVerschuurenJLammersGJResponse to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexyJ Neurol2007254111607160817762946
   PubMed Web of Science ®Google Scholar
• PlazziGPoliFFranceschiniCIntravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexyJ Neurol2008255101549155418769859
   PubMed Web of Science ®Google Scholar
• ValkoPOKhatamiRBaumannCRBassettiCLNo persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexyJ Neurol2008255121900190318825431
   PubMed Web of Science ®Google Scholar
• LecendreuxMMaretSBassettiCMourenMCTaftiMClinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boyJ Sleep Res2003124347348 Letter14633248
   PubMed Web of Science ®Google Scholar
• DauvilliersYCarlanderBRivierFTouchonJTaftiMSuccessful management of cataplexy with intravenous immunoglobulins at narcolepsy onsetAnn Neurol200456690590815562415
   PubMed Web of Science ®Google Scholar
• DauvilliersYFollow-up of four narcolepsy patients treated with intravenous immunoglobulinsAnn Neurol200660115316802296
   PubMed Web of Science ®Google Scholar
• DauvilliersYAbrilBMasEMichelFTaftiMNormalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatmentNeurology200973161333133419841387
   PubMed Web of Science ®Google Scholar
• KnudsenSMikkelsenJDBangBGammeltoftSJennumPJIntravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexyNeuropediatrics201041521722221210337
   PubMed Web of Science ®Google Scholar
• KnudsenSBiering-SorensenBKornumBREarly IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiencyNeurology201279110210322722630
   PubMed Web of Science ®Google Scholar